What employers & payers need to know about multi-cancer early detection tests

For decades, cancer screening has meant one test for each type of cancer — and only for the handful of cancers with established guidelines. However, a new type of cancer screening test is generating significant interest among employers, payers, and regulatory bodies. Multi-cancer early detection (MCED) tests use a single blood draw to look for signs of dozens of cancers, including many that do not have routine screening tests today. 

On September 23, 2026, an FDA advisory committee reviewed Galleri, the first MCED test to undergo a formal FDA review, and the panel voted 7-2 (with one abstention) that the benefits of Galleri outweigh its risks and recommended the test for approval. While a final FDA decision is not expected until early 2027, the review could influence future adoption, insurance coverage, and employer benefit strategies.  

Why this is on benefit leaders’ radar

Cancer is one of the largest drivers of healthcare spend, particularly when it is diagnosed at later stages. Truven’s MarketScan data shows late-stage cancers cost five to 10 times more to treat than cancers caught at the earliest stage, with the gap widening over the past five years (partially due to new treatments like targeted therapies and CAR-T). The appeal of MCED testing is straightforward: find cancer sooner, when treatment may be more effective and less expensive.

Galleri is a blood test designed to detect cancer-related DNA signals from more than 50 cancers and identify the type and origin most likely responsible for those signals. It is proposed for individuals at an elevated risk for cancer, such as adults 50 and older and intended to be used alongside recommended cancer screenings, not as a replacement for them.  

What the evidence does and does not show

While the technology is promising, employers and plans should understand its limitations. 

The evidence is still evolving. Results from the NHS-Galleri study showed some increase in early cancer detection, but did not demonstrate a significant reduction in late-stage cancers, a key measure of whether screening ultimately improves outcomes.  Researchers continue to analyze results from large studies.    

The stage shift potential is real but modest. Because MCED tests are least sensitive for the smallest, earliest-stage tumors, they are more likely to shift some cancers from advanced metastatic disease to earlier invasive stages than to detect cancers in situ. Savings models built on earliest-stage cost avoidance will overstate return. 

False results cut both ways. Like any screening test, MCED tests can sometimes suggest cancer is present when it is not. Galleri’s specificity is high at 99.6%, and roughly six in 10 positive results are confirmed as cancer. Still, about four in 10 members with a positive result will undergo imaging, specialist visits, and sometimes biopsy before cancer is ruled out — a process that took a median of 79 days to resolution in one study. These follow-up tests can increase healthcare costs and create anxiety for employees and their families.  

The opposite can also occur. A negative result is not a clean bill of health, and members should continue their recommended screenings and seek medical attention when symptoms or concerns arise.  

Perhaps the most important question for employers is not whether the test is perfect at detecting cancer signals, but whether it improves outcomes. Does it help find more cancers before they become advanced? Does it improve survival? Does it reduce overall healthcare costs?

What to do before you decide

Quantifying exposure ahead of a coverage decision is straightforward with claims data:

• Size the eligible population — members aged 50 and older, with optional stratification by prior cancer history, smoking-related disease, or screening non-compliance  

• Model gross spend at the $949 list price across realistic uptake scenarios, not full eligibility — and confirm your actual negotiated rate, since discounted pricing is available to some employers and carriers, and cost varies by ordering practice setting

• Benchmark your own stage-at-diagnosis mix and late-stage spend to establish the offset required to break even

• Verify navigation capacity including eligibility management, medical policy and prior authorization criteria, care navigation, PCP availability for workup, and behavioral health support through a diagnostic interval that can run weeks

• Continue to follow emerging evidence and regulatory developments closely. Even if FDA approval is granted, coverage decisions are likely to vary as health plans and employers evaluate the clinical value and cost implications of these tests.

Using insights from Truven for coverage decisions

MCED tests offer an innovative approach to detecting cancers that may otherwise go undiagnosed until later stages. However, important questions remain about their impact on health outcomes and healthcare costs. Until more evidence becomes available, employers and plans should carefully weigh the potential benefits against the costs and challenges associated with broader adoption. 

Whether you are evaluating coverage now or watching for the FDA decision, Truven can help you size eligible populations, model cost exposure, and benchmark stage-at-diagnosis trends against your own claims experience. Connect with our team today to learn more.